1998714-25-2
Chemical Structure
LY3325656
- CAS No.: 1998714-25-2
- Formula:C21H23F3N6O2
- Molecular Weight:448.45
IUPAC Name: N-((2S,4R)-2-(5-(1,4-dimethyl-1H-imidazol-5-yl)-4H-1,2,4-triazol-3-yl)tetrahydro-2H-pyran-4-yl)-N-methyl-3-(trifluoromethyl)benzamide
InChIKey: LEKZBCFOSTUBJZ-CVEARBPZSA-N
SMILES: CC1=C(N(C)C=N1)C=2NC(=NN2)[C@@H]3C[C@H](N(C(=O)C4=CC(C(F)(F)F)=CC=C4)C)CCO3
Biological Activity: LY3325656 is a selective GPR142 receptor agonist. LY3325656 selectively activates GPR142 in humans and mice. LY3325656 enhances glucose-dependent insulin secretion, glucagon secretion, as well as the secretion of incretin hormones GLP-1 and GIP. LY3325656 can be used in research related to type 2 diabetes[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
LY3325656 | LY3325656 is a selective GPR142 receptor agonist. LY3325656 selectively activates GPR142 in humans and mice. LY3325656 enhances glucose-dependent insulin secretion, glucagon secretion, as well as the secretion of incretin hormones GLP-1 and GIP. LY3325656 can be used in research related to type 2 diabetes. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Liu LZ, et al. Discovery of LY3325656: A GPR142 agonist suitable for clinical testing in human. Bioorganic & medicinal chemistry letters. 2020 Mar 01;30(5):126857. [Content Brief]
- [2]. Pratt EJ, et al. 20‑OR: GPR142 Agonists Increase Glucose‑Dependent Insulin Secretion and Differentially Regulate Hormone Secretion in Preclinical and Phase 1 Studies. Diabetes. 2019;68(Suppl 1):20‑OR.
